menu

Loading...

NBY Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

1.699

Open

1.350

VWAP

1.47

Vol

462.51K

Mkt Cap

37.07M

Low

1.290

Amount

681.28K

EV/EBITDA(TTM)

--

Total Shares

25.92M

EV

39.78M

EV/OCF(TTM)

9.78

P/S(TTM)

0.55

NovaBay Pharmaceuticals, Inc. is engaged in wound care products. The Company manufactures and sells its proprietary form of hypochlorous acid for the wound care market through its NeutroPhase and PhaseOne branded products. NeutroPhase and PhaseOne are used for cleansing and irrigation as part of surgical procedures, as well as treating wounds, burns, ulcers and other injuries.

Show More

Events Timeline

(ET)

2026-01-20

09:50:00

NovaBay Trading Resumes

2026-01-20

09:40:00

NovaBay Trading Halted Due to Volatility

2026-01-13 (ET)

2026-01-13

12:10:00

NovaBay Shares Drop 14.2% to $11.54

2026-01-13

10:10:00

NovaBay Shares Drop 17.1% to $11.15

2026-01-13

09:50:00

NovaBay Trading Resumes

2026-01-13

09:40:00

NovaBay Trading Halted Due to Volatility

2025-10-20 (ET)

2025-10-20

19:09:19

NovaBay Meets NYSE American Continued Listing Requirements Again

2025-08-26 (ET)

2025-08-26

16:11:38

NovaBay announces special cash dividend of 80 cents per share

2025-08-19 (ET)

2025-08-19

17:26:50

NovaBay Signs $6M Securities Purchase Agreement with David Lazar

News

Benzinga

Netflix Reports Q4 Results, Q1 Guidance Misses Estimates

Benzinga

D.R. Horton Reports Q1 Net Income of $594.8M Exceeding Estimates

seekingalpha

01-20seekingalpha

NovaBay Pharmaceuticals (NBY) Announces $100M Stock Sale Agreement with Virtu Americas

Benzinga

J.B. Hunt Reports Q4 Revenue Slightly Below Estimates, Shares Drop 4.2%

Benzinga

RF Industries Reports $22.7M Q4 Sales, Shares Surge 21.4%

Benzinga

Glaukos Corp (GKOS) Projects FY25 Sales of $507 Million, Shares Drop 12.1%

Valuation Metrics

The current forward P/E ratio for NovaBay Pharmaceuticals Inc (NBY.A) is -6.83, compared to its 5-year average forward P/E of -1.97. For a more detailed relative valuation and DCF analysis to assess NovaBay Pharmaceuticals Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-1.97

Current PE

-6.83

Overvalued PE

-0.34

Undervalued PE

-3.60

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-5.55

Current EV/EBITDA

-285.64

Overvalued EV/EBITDA

19.88

Undervalued EV/EBITDA

-30.98

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

1.50

Current PS

61.64

Overvalued PS

6.99

Undervalued PS

-3.99

Financials

AI Analysis

Annual

Quarterly

Whales Holding NBY

Trading Trends

People Also Watch

Frequently Asked Questions

What is NovaBay Pharmaceuticals Inc (NBY) stock price today?

The current price of NBY is 1.43 USD — it has decreased -0.69

What is NovaBay Pharmaceuticals Inc (NBY)'s business?

NovaBay Pharmaceuticals, Inc. is engaged in wound care products. The Company manufactures and sells its proprietary form of hypochlorous acid for the wound care market through its NeutroPhase and PhaseOne branded products. NeutroPhase and PhaseOne are used for cleansing and irrigation as part of surgical procedures, as well as treating wounds, burns, ulcers and other injuries.

What is the price predicton of NBY Stock?

Wall Street analysts forecast NBY stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for NBY is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is NovaBay Pharmaceuticals Inc (NBY)'s revenue for the last quarter?

NovaBay Pharmaceuticals Inc revenue for the last quarter amounts to 521.00K USD, decreased

What is NovaBay Pharmaceuticals Inc (NBY)'s earnings per share (EPS) for the last quarter?

NovaBay Pharmaceuticals Inc. EPS for the last quarter amounts to -1.10 USD, decreased -88.54

How many employees does NovaBay Pharmaceuticals Inc (NBY). have?

NovaBay Pharmaceuticals Inc (NBY) has 14 emplpoyees as of March 02 2026.

What is NovaBay Pharmaceuticals Inc (NBY) market cap?

Today NBY has the market capitalization of 37.07M USD.